Physician profile
Anthony Gross
NPI 1942615182
$2,499.01
in general payments reported to CMS, 2019-2025
25 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $314 · 2021: $70.65 · 2022: $723 · 2023: $435 · 2024: $435 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.51 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Centinel Spine, LLC | $597.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $541.50 | 2022-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.95 | 2023-2025 | Caplyta |
| Abbvie INC. | $169.64 | 2024 | |
| Pfizer INC. | $167.65 | 2020-2025 | |
| Alphatec Spine, INC | $142.41 | 2019 | |
| Axsome Therapeutics, INC. | $86.12 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $74.31 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $71.58 | 2023-2024 | Rexulti, Abilify Mycite |
| Novo Nordisk INC | $57.47 | 2019-2020 | |
| Amgen INC. | $52.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.31 | 2019-2020 | |
| Almatica Pharma LLC | $35.83 | 2023 | Loreev Xr |
| Glaxosmithkline, LLC. | $34.73 | 2020 | |
| Trice Medical, INC. | $32.28 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $24.97 | 2025 | Vyepti |
| Ibsa Pharma INC. | $19.82 | 2023 | Tirosint, Licart |
| Tonix Medicines, INC. | $18.46 | 2025 | Zembrace Symtouch |
| Kci USA, INC. | $18.29 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.26 | 2021 | |
| Lilly USA, LLC | $17.35 | 2021 | |
| Eisai INC. | $16.75 | 2021 | |
| Amarin Pharma, INC. | $15.87 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.59 | 2019 | |
| Allergan, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.